1. 227 Predictive serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01). (September 2015) Authors: Pineda Losada, E.; Salud, A.; Vila-Navarro, E.; Safont, M.J.; Garcia-Giron, C.; Aparicio, J.; Vera, R.; Escudero, M.P.; Casado, E.; Bosch, C.; Bohn, U.; Perez Carrion, R.M.; Carmona Bayonas, A.; Ayuso, J.R.; Ripolles, T.; Bouzas, R.; Gironella, M.; Garcia-Albeniz, X.; Feliu, J.; Maurel, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale. Issue 5 (September 2015) Authors: Bonanad, S.; De la Rubia, J.; Gironella, M.; Pérez Persona, E.; González, B.; Fernández Lago, C.; Arnan, M.; Zudaire, M.; Hernández Rivas, J.A.; Soler, A.; Marrero, C.; Olivier, C.; Altés, A.; Valcárcel, D.; Hernández, M.T.; Oiartzabal, I.; Fernández Ordoño, R.; Arnao, M.; Esquerra, A.; Sarrá, J. Journal: Journal of geriatric oncology Issue: Volume 6:Issue 5(2015) Page Start: 353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1588: A SINGLE CENTER COMPARATIVE CLINICAL ANALYSIS OF THE SARS-COV-2 INFECTION BEFORE AND AFTER VACCINATION IN PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCIES. (23rd June 2022) Authors: Jiménez, M.; Novoa, S.; Fernandez-Naval, C.; Navarro, V.; Andrés, C.; Martínez-Gallo, M.; Antón, A.; Fox, L.; Roldán, E.; Cabirta, A.; Gironella, M.; Orti, G.; Barba, P.; Medina, D.; Peralta, S.; Pujadas, G.; Hernández, C.; Pages, C.; Pumarola, T.; Valentin, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1469 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS. (23rd June 2022) Authors: Quach, H.; Gironella, M.; Lee, C.; Popat, R.; Cannell, P.; Kasinathan, R. S.; Chopra, B.; Rogers, R.; Ferron-Brady, G.; Shafi-Harji, S.; Patel, N.; Opalinska, J.; Gupta, I.; Augustson, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 831 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PB2002: OBSERVATIONAL PROSPECTIVE STUDY TO INVESTIGATE THE RELATIONSHIP BETWEEN DURATION OF TREATMENT AND RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA OR AL AMYLOIDOSIS: THE DORIANT STUDY (NCT: 04659798). (23rd June 2022) Authors: Grande, M.; Naves, A.; Aparicio, J.; Gironella, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1873 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗